Regeneron Presents Eye Treatment Results With EYLEA HD at Vision Research Meeting
Regeneron Presents Eye Treatment Results With EYLEA HD at Vision Research Meeting
Regeneron 在视觉研究会议上展示使用 EYLEA HD 的眼部治疗结果
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA HD (aflibercept) Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA (aflibercept) Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting from May 5 to 9 in Seattle.
Regeneron Pharmicals, Inc.（纳斯达克股票代码：REGN）今天宣布公布了8毫克EYLEA HD（aflibercept）注射液关键临床项目的积极长期结果和亚组分析。这些演讲是14份关于EYLEA HD和EYLEA（aflibercept）注射液2 mg的摘要的一部分，这些摘要将在5月5日至9日在西雅图举行的视觉与眼科学研究协会（ARVO）年会上分享。